Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 493 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High Cardiovascular Risk Clear all
Active, not recruiting Not applicable Interventional

HIIT Following Breast Cancer Chemotherapy

NCT05913713
View directory record Official record
Conditions
Breast Cancer
Interventions
12-week Intervention Period, 12-week Observation Period
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 3:24 AM EDT
Recruiting No phase listed Observational

A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction

NCT05332262
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Assessment of platelet reactivity, Troponin measurement
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 3 Interventional Results available

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT06005597
View directory record Official record
Conditions
Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Interventions
Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo
Combination Product · Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
45
States / cities
Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 3 Interventional Results available

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

NCT02104817
View directory record Official record
Conditions
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions
Epanova® (omega-3 carboxylic acids), corn oil control
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
13,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
229
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 183 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 4 Interventional Results available

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

NCT00346216
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
celecoxib, Ibuprofen, Naproxen
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
24,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
871
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 515 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620
View directory record Official record
Conditions
Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 3, 2026, 3:24 AM EDT
Recruiting Not applicable Interventional

A Dietary Study for People With Multiple Myeloma

NCT07226609
View directory record Official record
Conditions
Multiple Myeloma
Interventions
nutrition counseling and coaching, dietary guidelines, research dietitian visit, Questionnaires, Frozen pre-prepared meals
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

NCT01484275
View directory record Official record
Conditions
High-risk Smoldering Multiple Myeloma
Interventions
Siltuximab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
Chicago, Illinois • Rockville, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 3, 2026, 3:24 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
15,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
357
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 2 Interventional

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

NCT00006219
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
clarithromycin, prasterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 3, 2026, 3:24 AM EDT
Active, not recruiting Not applicable Interventional

Mediterranean-DASH Intervention for Neurodegenerative Delay and High-Intensity Interval Training in Adults With Hypertension

NCT07130539
View directory record Official record
Conditions
Hypertension (HTN), Obesity &Amp; Overweight, Sedentary
Interventions
MIND HIIT
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 74 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 3, 2026, 3:24 AM EDT
Recruiting Phase 2 Interventional

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

NCT06100237
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Daratumumab SC
Drug
Lead sponsor
Carl Ola Landgren, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The CASCADE HF Soft Launch and Calibration Phase I and II

NCT04738279
View directory record Official record
Conditions
Heart Failure
Interventions
Non-Invasive Continuous Remote Patient Monitoring, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
Device · Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 3, 2026, 3:24 AM EDT
Not yet recruiting Not applicable Interventional

Reducing Cardiovascular Risks: The Role of Alcohol Use

NCT07783061
View directory record Official record
Conditions
Alcohol Drinking, Drinking Behavior, At-risk Drinking, Cardiovascular Risk Factor, High Blood Pressure
Interventions
Alcohol Abstinence, Control arm
Behavioral · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
26 Years to 49 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 2 Interventional

Personalized Antiplatelet Secondary Stroke PRevenTion

NCT03979781
View directory record Official record
Conditions
Ischemic Stroke, TIA
Interventions
tailored antiplatelet selection, standard of care
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Not applicable Interventional

IMpella-Protected cArdiaC Surgery Trial (IMPACT)

NCT05529654
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Impella 5.5 with SmartAssist
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Jonesboro, Arkansas • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Not applicable Interventional

Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease

NCT02646488
View directory record Official record
Conditions
Cardiovascular Disease, High Blood Pressure
Interventions
Million Hearts ABCS 6 Months, Million Hearts ABCS 9 Months, Million Hearts ABCS 12 Months, Million Hearts ABCS 15 Months, Standard Care Regimen 9 Months, Standard Care Regimen 12 Months, Standard Care Regimen 15 Months, Standard Care Regimen 18 Months, Standard Care Regimen 21 Months, Standard Care Regimen 24 Months, Standard Care Regimen 27 Months, Follow Up Post Intervention 21 Months, Follow Up Post Intervention 24 Months, Follow Up Post Intervention 27 Months, Follow Up Post Intervention 30 Months, Follow Up Post Intervention 33 Months
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2019 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Postprandial Monocyte Maturation and Vascular Dysfunction Following High-Fat Meals - Study 1

NCT03958734
View directory record Official record
Conditions
Cardiovascular Risk Factor, Lipemia
Interventions
High-fat meal
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 30 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Not applicable Interventional

The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk

NCT01008384
View directory record Official record
Conditions
Atherosclerosis
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 3, 2026, 3:24 AM EDT
Active, not recruiting Phase 2 Interventional

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT00869232
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 2 Interventional Results available

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

NCT01760655
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Leukemia, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Fludarabine phosphate, Busulfan, Total-Body Irradiation, Therapeutic Allogeneic Lymphocytes, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Biological + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 3, 2026, 3:24 AM EDT
Withdrawn Not applicable Interventional

Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients

NCT02707263
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
intravenous continuous infusion of heparin (IV UFH), Subcutaneous Heparin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 3, 2026, 3:24 AM EDT
Recruiting Not applicable Interventional

Technology-enabled Management Versus Usual Care for Blood Pressure

NCT05479461
View directory record Official record
Conditions
Hypertension
Interventions
Digital Hypertension Management System, Usual Care
Other
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Palo Alto, California • Atlanta, Georgia • Eatonton, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 3, 2026, 3:24 AM EDT